Promising new therapy targets rare, aggressive cancers
NCT ID NCT06444880
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests whether the drug ubamatamab, alone or with cemiplimab, can help control rare cancers like renal medullary carcinoma and epithelioid sarcoma. About 40 adults with advanced or metastatic disease will receive the treatment to check safety and effectiveness. The goal is to shrink or slow tumor growth in people who have few other options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat childhood cancers?
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Experimental drug opens door for rare sarcoma patients with no options left
- New scan could spot hidden tumors more accurately
- New combo shows promise for rare kidney cancers
- Last-Resort drug opens for rare cancer patients